Prove its efficacy and safety first


(FILES) In this file photo taken on October 17, 2018, a marijuana plant is pictured in Vancouver, Canada. - Canadian cannabis producer Aphria on Friday, December 28, 2018 rejected a proposed Can2.8 billion (2.1 billion US) takeover bid by US-based Xanthic Biopharma, calling it hostile and under-valued. Green Growth Brands, a division of Xanthic Biopharma, presented a conditional offer of Can11 per share on December 27, 2018 after markets closed. (Photo by Don MacKinnon / AFP)

THE Star Online last week reported the Deputy Health Minister of Malaysia’s response to Thailand approving marijuana for medical use and research (tinyurl.com/star-cannabis). Marijuana is also known as cannabis, or ganja in Malay.

Accor­ding to Deputy Minister Dr Lee Boon Chye, pharmaceutical firms wishing to register the drug for such use must provide the required standard information on its quality, efficacy and safety.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Letters

China-Asean free trade area 3.0: Opening a new chapter in regional cooperation
Train seniors to avoid scams
Singapore model offers insight into legal qualification
The journey towards a better digital economy
Consider unconditional cash transfer system
Towards enhancing efficiency
Get the messaging right, please
Food hygiene requires coordinated approach at all levels
Urgent call for tree management in Penang
Construction industry must reduce worksite fatalities

Others Also Read